I
Immix Biopharma, Inc. (IMMX)
NCM – Real vaqt narxi. Valyuta: USD
10.66
+0.74 (7.46%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
10.66
+0.74 (7.46%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Immix Biopharma, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, AQSh va Avstraliyada yengil zanjirli amiloidoz va immunitet vositachiligidagi kasalliklarda kimera antigen retseptorli hujayra terapiyasini ishlab chiqish bilan shug'ullanadi. Kompaniyaning asosiy mahsuloti takrorlanuvchi/refrakter AL amiloidoz uchun NXC-201 hisoblanadi. Immix Biopharma, Inc. 2012 yilda tashkil etilgan va shtab-kvartirasi Los-Anjelesda, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David Marks MBBS, Ph.D. | Chief Medical Officer of Cell Therapy |
| Dr. Graham Ross FFPM, M.D. | Chief Medical Officer & Head of Clinical Development |
| Dr. Ilya Rachman M.B.A., M.D., Ph.D. | Co-Founder, CEO, Chief Scientific Officer & Chairman |
| Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder |
| Mr. Gabriel Morris B.A. | President, CFO & Director |
| Mr. Mel Davis-Pickett | Head of CMC Technical Development |
| Mr. Michael A. Grabow | Chief Commercial Officer |
| Mr. Sean Senn J.D., M.B.A., M.Sc. | Co-Founder |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | form10-q.htm |
| 2026-04-06 | DEF 14A | formdef14a.htm |
| 2026-03-30 | 8-K | form8-k.htm |
| 2026-03-27 | 10-K/A | form10-ka.htm |
| 2026-01-16 | CORRESP | filename1.htm |
| 2026-01-09 | S-3 | forms-3.htm |
| 2025-12-08 | 8-K | form8-k.htm |
| 2025-11-26 | CORRESP | filename1.htm |
| 2025-11-26 | 8-K | form8-k.htm |
| 2025-11-07 | 10-Q | form10-q.htm |